← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	4,117	+225	+6%	$251B
2	2 AbbVie ABBV $501B	3,752	+246	+7%	$227B
3	3 Merck MRK $358B	3,616	+118	+3%	$197B
4	4 Pfizer PFE $168B	3,004	+87	+3%	$99.6B
5	5 Amgen AMGN $235B	2,862	+32	+1%	$109B
6	6 Bristol-Myers Squibb BMY $124B	2,495	+229	+10%	$90.4B
7	7 Gilead Sciences GILD $195B	1,890	+169	+10%	$98.2B
8	8 Novartis NVS $286B	1,342	+29	+2%	$12.7B
9	9 Regeneron Pharmaceuticals REGN $82B	1,321	-71	-5%	$66.7B
10	10 AstraZeneca AZN $259B	1,221	-10	-0.8%	$33.7B
11	11 GSK GSK $98.2B	850	-51	-6%	$11.6B
12	12 Incyte INCY $23B	651	+59	+10%	$12.6B
13	13 Natera NTRA $58.3B	596	+101	+20%	$19.8B
14	14 DELISTED Exact Sciences EXAS	595	-5	-0.8%	$10.3B
15	15 Exelixis EXEL $15.6B	520	+67	+15%	$8.33B
16	16 Halozyme HALO $13.8B	509	+1	+0.2%	$5.86B
17	17 Jazz Pharmaceuticals JAZZ $13.9B	509	+31	+6%	$7.28B
18	18 Lantheus LNTH $6.53B	487	-12	-2%	$6.68B
19	19 DELISTED Blueprint Medicines BPMC	346	+27	+8%	$5.86B
20	20 Qiagen QGEN $9.53B	326	-5	-2%	$6.6B
21	21 Veracyte VCYT $3.57B	318	+26	+9%	$3.25B
22	22 Recursion Pharmaceuticals RXRX $2.23B	316	+49	+18%	$2.06B
23	23 BioNTech BNTX $22.7B	303	+7	+2%	$5.79B
24	24 Takeda Pharmaceutical TAK $62.1B	302	+2	+0.7%	$954M
25	25 Iovance Biotherapeutics IOVA $6.67B	301	+15	+5%	$1.79B